Related references
Note: Only part of the references are listed.New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Rafeeq Ali et al.
ANNALS OF MEDICINE (2009)
Thiazolidinediones in NASH An Odd Couple Meant To Be?
Kenneth Cusi
JOURNAL OF CLINICAL GASTROENTEROLOGY (2009)
Recent advances in nonalcholic fatty liver disease
Victoria Greenfield et al.
CURRENT OPINION IN GASTROENTEROLOGY (2008)
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects
Kevin M. Korenblat et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Role of peiroxisome proliferators-activated receptors in the pathogenesis and treatment of nonaloholic fatty liver disease
Eric R. Kallwitz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver
Gianluca Perseghin et al.
HEPATOLOGY (2008)
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects
Amalia Gastaldelli et al.
GASTROENTEROLOGY (2007)
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes
Kenneth Cusi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Inflammation in diabetes mellitus:: Role of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists
Peter Libby et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The effect of pioglitazone on the liver - Role of adiponectin
Amalia Gastaldelli et al.
DIABETES CARE (2006)
Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states
BR Barrows et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it
K Begriche et al.
MITOCHONDRION (2006)
Mechanisms of Disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance
Michael Roden
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Lessons from animal models of NASH
AM Diehl
HEPATOLOGY RESEARCH (2005)
Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo
I Bogacka et al.
DIABETES (2005)
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
E Bugianesi et al.
DIABETOLOGIA (2005)
Adiponectin:: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?
M Bouskila et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
H Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes
M Tiikkainen et al.
DIABETES (2004)
Molecular mediators of hepatic steatosis and liver injury
JD Browning et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis
Arun J. Sanyal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo
I Bogacka et al.
DIABETES CARE (2004)
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
M Bajaj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes
S Kashyap et al.
DIABETES (2003)
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
T Yamauchi et al.
NATURE MEDICINE (2002)
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men
A Seppälä-Lindroos et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
Y Miyazaki et al.
DIABETOLOGIA (2001)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects
G Boden et al.
DIABETES (2001)
Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARγ mRNA expression in 3T3-L1 adipocytes
T Takamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
AJ Sanyal et al.
GASTROENTEROLOGY (2001)
Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
JM Olefsky
JOURNAL OF CLINICAL INVESTIGATION (2000)
A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis
M Gurnell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
